PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

21 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024

18 Nov 2024 18:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

07 Nov 2024 16:05:02 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the Stifel Healthcare Conference

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024

17 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

01 Oct 2024 16:35:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2024 16:45:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024

10 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

28 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024

26 Aug 2024 09:10:07 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

07 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

06 Aug 2024 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures

15 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

13 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

12 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

06 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

21 May 2024 18:50:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

14 May 2024 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™

07 May 2024 08:00:01 By Nasdaq GlobeNewswire